ARKANCE and Eagle Point Software Extend Partnership to EMEA
28.5.2025 15:41:00 CEST | Business Wire | Press Release
ARKANCE, a global leader in digital transformation solutions for the architecture, engineering, and construction (AEC) and manufacturing industries, and Eagle Point Software are extending their partnership to the EMEA region. Building on years of collaboration across the United States and Asia-Pacific, the strengthened global alliance now also delivers next-generation e-learning and digital training solutions to customers across Europe.
As AEC firms work to close skills gaps and keep pace with digital transformation, attracting and enabling the next generation of talent is essential. Studies show that 65% of Gen Z say they prefer online learning over in-person classrooms1, making on-demand, cloud-based learning more attractive to new professionals. This makes on-demand, cloud-based learning not just attractive, but urgent.
With the extension of the partnership to EMEA, ARKANCE will become the largest global reselling partner for Pinnacle Series, Eagle Point’s premier Learning Management System (LMS) and Pinnacle Lite, the solution provider’s eLearning software. Eagle Point will also enhance its global footprint and deliver the industry-standard for learning tools in AEC and manufacturing across the world.
With personalized learning journeys, skills assessments, and comprehensive training libraries professionals can master leading tools such as AutoCAD, Revit, Bluebeam, and more. It supports both individual learning and organization-wide knowledge sharing.
Greg Arranz, CEO at ARKANCE says: “Our goal is to help our customers build smarter with digital solutions. To meet the continuous learning needs of a new generation of engineers and designers, Pinnacle is the perfect partner. Together, we can help teams level up capabilities on the latest innovations from world-class technology providers. They can then advance to deeper learning with ARKANCE specific content and consulting from our experts. Pinnacle Series also provides capabilities for customization and development of a comprehensive learning plan for customers who need to offer training on their own processes or tools.”
In the EMEA region, ARKANCE will build on its historic strength in instructor-led, local language training to provide a hybrid model that combines the flexibility of on-demand learning with the depth of personalized consultation and face-to-face instruction.
“This partnership represents a significant milestone for Eagle Point Software’s global expansion, allowing us to help hundreds of thousands more people,” said Steve Biver, Chief Operating Officer at Eagle Point Software. “Pinnacle Series is more than software training – it’s about rethinking how organizations onboard, upskill, and support teams. ARKANCE’s deep expertise in the AEC and Manufacturing industries makes them a great partner to scale the value of Pinnacle Series worldwide.”
About Eagle Point Software
Since 1983, Eagle Point Software has focused on increasing productivity for AEC and manufacturing professionals. The company’s flagship solution, Pinnacle Series, offers a powerful eLearning platform that drives user adoption of software like Autodesk, Microsoft, and Bluebeam. With over 500,000 users worldwide, Pinnacle Series supports firms in achieving higher performance through continuous learning.
About ARKANCE
ARKANCE, a subsidiary of the French B2B services leader Monnoyeur Group, is a global partner in the digital transformation of the construction and manufacturing sectors. Founded in 2018, ARKANCE operates in over 20 countries, delivering expert professional services, innovative solutions, and advanced training. Our teams combine proprietary Be.Smart software with technologies from a network of world-class partners to help customers bridge the gap between design and operations. With 1,300+ professionals, we empower businesses to build resilience, increase profitability, and improve project outcomes.
For more information on ARKANCE visit our website : https://arkance.world/gb-en/services/eagle-point-pinnacle
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513736456/en/
Contacts
media@arkance.world
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom